Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Tao OUYANG
Updated on 26 January 2021


This is a phase IV, single-center, prospective, open-label, randomized,controlled study

Condition Primary Breast Cancer
Treatment Vinorelbine
Clinical Study IdentifierNCT03270007
SponsorTao OUYANG
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Female patients, 18age 66 years
Biopsy proven lymph node positive, estrogen receptor<10%progesterone receptor <10% and human epidermal growth factor receptor-2 negative primary breast cancer
Must have completed neo-adjuvant chemotherapy with a standard regimen(containing both anthracycline and paclitaxel)
Must have undergone surgery to remove the primary tumor by either a mastectomy or enlarged local excision
Postoperative residual positive lymph nodes
Adequate recovery from recent surgery
No history of other malignancies
No currently uncontrolled diseased or active infection
Not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential
Adequate cardiovascular function reserve with a myocardial infarction within the past six month
without radiotherapy and chemotherapy contraindication
Adequate hematologic function with
Absolute neutrophil count (ANC) 1500/mm3
Platelets 100,000/ mm3
Hemoglobin 10 g/dL
Adequate hepatic and renal function with
Serum bilirubin 1.5UNL
Alkaline phosphatase and alanine aminotransferase (ALT) 2.5 x ULN. (5 x ULN is acceptable in the setting of hepatic metastasis)
BUN between 1.7 and 8.3 mmol/L
Cr between 40 and 110 umol/L
Knowledge of the investigational nature of the study and Ability to give informed consent
Ability and willingness to comply with study procedures

Exclusion Criteria

Known or suspected distant metastases
Concurrent malignancy or history of other malignancy
Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or active infection
Geographical, social, or psychological problems that would compromise study compliance
Known or suspected hypersensitivity to vinorelbine
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note